Translating Scientific Breakthroughs into Promise for Patients

From discovery through commercialization, all of us at Ardelyx are driven to advance targeted therapies where significant medical needs persist. We have developed a unique and innovative platform that has enabled the discovery of new biological mechanisms and pathways to create targeted, first-in-class, oral, small molecule therapies to meet these needs. Our lead candidate, tenapanor, is currently under FDA review for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.

With Integrity and Dedication, We Make a Difference for Patients

Join Us

We are… Passionate. Fearless. Dedicated. Inclusive!

Patients & Families

Translating scientific breakthroughs into promise for patients.

For Investors

Creating value from

Recent News

July 29, 2021

Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application...

July 19, 2021

Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the...

June 7, 2021

Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021